TSTickerStarGet alerts
Company alerts/LCID
LCID company alerts

LCID updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for LCID. Subscribe to LCID alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for LCID alertsView companies
Official-source feed

Recent LCID alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Debt offeringSEC filing

Lucid Diagnostics starts Medicare reimbursement for EsoGuard and closes $15 million preferred-stock placement

Lucid Diagnostics Inc. said it is submitting Medicare claims for EsoGuard tests and receiving payments at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test. It closed a $15.0 million private placement of newly designated Series C Convertible Preferred Stock on October 21, 2026, at $1,000 per share and a conversion price of $0.3519 per common share. Existing long-term shareholders participated, including holders of a majority of the company's 12.0% senior secured convertible notes due 20...

Read source-backed brief
Company updateOfficial company source

Lucid draws $400M of Delayed Draw Term Loan facility from PIF affiliate

On October 6, 2026, Lucid Group, Inc. drew $400 million of Delayed Draw Term Loan (DDTL) facilities under its existing agreement with Ayar Third Investment Company, an affiliate of the Public Investment Fund. Following the draw, the aggregate principal amount outstanding under the DDTL is approximately $2.1 billion, with approximately $400 million of additional borrowing capacity remaining. The 8-K was filed on October 9, 2026 under Item 2.03 (Creation of a Direct Financial Obligation) and incorporates the key D...

Read source-backed brief